Non-small cell lung cancer
RecruitingStudy of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels
Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels
- Disease:Non-small cell lung cancer
- Substances:MK-1084Pembrolizumab
Greece- Participants:18–64 years · 65+ years
- Substances:MK-1084
- Sponsor:Merck Sharp & Dohme LLC












